Bromide

Bromide

SCHEMBL2993729

CCCCCCCCOCC(O)C[N+](C)(C)C.[Br-]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.67
HTT P42858 2/20 0.65
PRKD3 O94806 1/20 0.57
PRKCG P05129 1/20 0.57
PRKCB P05771 1/20 0.57
PRKCA P17252 1/20 0.57
PRKCH P24723 1/20 0.57
PRKCI P41743 1/20 0.57
PRKCE Q02156 1/20 0.57
PRKCQ Q04759 1/20 0.57
PRKCZ Q05513 1/20 0.57
PRKCD Q05655 1/20 0.57
PRKD1 Q15139 1/20 0.57
LPAR5 Q9H1C0 4/20 0.56
SPHK1 Q9NYA1 1/20 0.50
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
MEN1 O00255 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28132215 1.00 USP2 (0.67) USP2HTTPRKD3PRKCGPRKCB
Bromide SCHEMBL29115750 1.00 USP2 (0.67) USP2HTTPRKD3PRKCGPRKCB
SCHEMBL2918618 0.98 USP2 (0.69) USP2HTTPRKD3PRKCGPRKCB
SCHEMBL7726473 0.98 USP2 (0.69) USP2HTTPRKD3PRKCGPRKCB
SCHEMBL19206489 0.98 USP2 (0.69) USP2HTTPRKD3PRKCGPRKCB
SCHEMBL7721792 0.98 USP2 (0.69) USP2HTTPRKD3PRKCGPRKCB
SCHEMBL7722820 0.98 USP2 (0.69) USP2HTTPRKD3PRKCGPRKCB
Hydrochloric Acid SCHEMBL6419460 0.96 USP2 (0.67) USP2HTTPRKD3PRKCGPRKCB
Hydrochloric Acid SCHEMBL2992402 0.96 USP2 (0.67) USP2HTTPRKD3PRKCGPRKCB
Hydrochloric Acid SCHEMBL9706808 0.96 USP2 (0.67) USP2HTTPRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168450-A1 NOVEL BRANCHED ALKOXYLATES THOEN JOHAN A 2010-07-01 US claimed
EP-2152652-A1 NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF Dow Global Technologies Inc. (US) 2010-02-17 EP claimed
EP-2139833-A1 NOVEL BRANCHED ALKOXYLATES Dow Global Technologies Inc. (US) 2010-01-06 EP claimed
WO-2008134390-A1 NOVEL BRANCHED ALKOXYLATES DOW GLOBAL TECHNOLOGIES INC. (US) 2008-11-06 WO claimed
WO-2008134387-A1 NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF DOW GLOBAL TECHNOLOGIES INC. (US) 2008-11-06 WO claimed
US-20100179354-A1 NOVEL ALKOXY-ETHERS AND ALKOXYLATES THEREOF THOEN JOHAN A 2010-07-15 US disclosed
US-20100168450-A1 NOVEL BRANCHED ALKOXYLATES THOEN JOHAN A 2010-07-01 US disclosed
EP-2152652-A1 NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF Dow Global Technologies Inc. (US) 2010-02-17 EP disclosed
EP-2152653-A1 NOVEL ALKOXYLATE-CONTAINING COMPOSITIONS Dow Global Technologies Inc. (US) 2010-02-17 EP disclosed
EP-2139833-A1 NOVEL BRANCHED ALKOXYLATES Dow Global Technologies Inc. (US) 2010-01-06 EP disclosed
WO-2008134390-A1 NOVEL BRANCHED ALKOXYLATES DOW GLOBAL TECHNOLOGIES INC. (US) 2008-11-06 WO disclosed
WO-2008134387-A1 NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF DOW GLOBAL TECHNOLOGIES INC. (US) 2008-11-06 WO disclosed
WO-2008134389-A1 NOVEL ALKOXYLATE-CONTAINING COMPOSITIONS DOW GLOBAL TECHNOLOGIES INC. (US) 2008-11-06 WO disclosed
US-6392064-B2 REACTING AN ALCOHOL WITH EPICHLOROHYDRIN WITH ALKALI METAL HYDROXIDE AND PHASE TRANSFER CATALYST KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2002-05-21 US disclosed
US-20020004605-A1 Method of synthesizing glycidyl ether compounds in the absence of water and organic solvents KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 2002-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020004605-A1 Method of synthesizing glycidyl ether compounds in the absence of water and organic solvents TET2, DGAT1, ALKBH3 USP2 3857/4885HTT 1505/4885PRKD3 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.